Docebo (DCBO) EBITDA (2019 - 2026)

Docebo (DCBO) has 8 years of EBITDA data on file, last reported at $1.7 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA rose 18.89% year-over-year to $1.7 million; the trailing twelve-month figure through Mar 2026 stood at $21.3 million (up 3.63% YoY), and the FY2025 full-year result was $23.2 million, down 0.73% from the prior year.
• EBITDA for Q1 2026 stood at $1.7 million, down from $9.3 million in the prior quarter.
• Across five years, EBITDA topped out at $9.3 million in Q4 2025 and bottomed at -$1.5 million in Q2 2023.
• The 5-year median for EBITDA is $3.7 million (2022), against an average of $3.7 million.
• The widest annual swing landed in 2023, when EBITDA sank 148.0%; it then soared 2010.7% in 2024.
• A 5-year view of EBITDA shows it stood at $2.5 million in 2022, then jumped by 145.39% to $6.3 million in 2023, then surged by 46.51% to $9.2 million in 2024, then climbed by 1.92% to $9.3 million in 2025, then slumped by 81.34% to $1.7 million in 2026.
• The last three EBITDA figures came in at $1.7 million (Q1 2026), $9.3 million (Q4 2025), and $6.0 million (Q3 2025), per Business Quant data.

Peer Comparison